61 drugs found substandard in 19 pharmaceutical industries in Himachal

Nalagarh:  As many as 24 medicines, syrups and injections manufactured in 19 pharmaceutical industries in Himachal Pradesh have been found to be substandard in a probe conducted by the Central Drugs Standard Control Organisation (CDSCO). Medicines that have not met the quality scale.

According to the information, they include medicines used in the treatment of pain including fungal infections, cancer, type 2 diabetes, severe bacterial infections, cardiac arrest, antibiotics, respiratory diseases, anti-inflammatory drugs, angina, Alzheimer’s, antiparasitic, stomach ulcers, fever.

These medicines have been manufactured in pharmaceutical industries located in Baddi, Barotiwala, Waknaghat, Paonta Sahib. Five samples from the Baddi-based Effi Pharma industry have failed. The state drug control authority has already taken action against this industry and banned the production of the drug.

In the drug alert issued by the CDSCO for the month of October, 37 drugs manufactured in New Delhi, Jammu, Rajasthan, Bihar Uttarakhand, Bengaluru, Kolkata, Uttar Pradesh, Punjab, Rajasthan, Gujarat, Maharashtra, Chennai have also been found to be substandard.

The State Drug Controller has issued notices to all the pharmaceutical companies involved in the drug alert and has issued instructions to immediately recall the entire batch of the concerned drug from the market. Along with this, assistant drug controllers have been instructed to jointly inspect all pharmaceutical industries and submit a detailed investigation report.

Meanwhile, State Drug Controller Navneet Marwah said that show-cause notices have been issued to all the concerned pharmaceutical companies involved in the drug alert for the month of October issued by the CDSCO and instructions have been given to recall the entire stock of the concerned batch. Apart from this, strict action will be taken against those industries whose samples are failing repeatedly.

Related Posts

  • Pharma
  • June 6, 2025
  • 301 views
Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

Mumbai-based pharma major Wockhardt, which is all set to launch its new class of antibiotic Zaynich targeted at treating complicated gram-negative infections in India this year, estimates that the drug…

  • Pharma
  • June 6, 2025
  • 184 views
Fake cosmetics racket busted in Bhubaneswar’s Unit-1 Market

In a joint crackdown, Odisha’s Drugs Control administration and Crime Branch Special Task Force (STF) raided Unit-1 Market in Bhubaneswar on Thursday, seizing duplicate cosmetic products sold under top brand…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

Fake cosmetics racket busted in Bhubaneswar’s Unit-1 Market

Fake cosmetics racket busted in Bhubaneswar’s Unit-1 Market

Illegally stocked drugs worth Rs 5.21 lakh seized

Illegally stocked drugs worth Rs 5.21 lakh seized

Patanjali and AIIMS Bhopal partner to develop holistic treatment solutions

Patanjali and AIIMS Bhopal partner to develop holistic treatment solutions